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Introduction: The functional status of pancreatic grafts in diabetic
patients is today assessed by indirect circulating markers such as
c-peptide and HbA1C. The lack of direct, non-invasive assessments
of beta cell function in these sensitive grafts is an obstacle for opti-
mized patient management. Serotonin has been associated with in-
sulin secretion [1-2] and beta cell proliferation [3], and is not
facilitated in the exocrine pancreas. We therefore posited that the se-
rotonergic biomarker [11C]5-Hydroxy-tryptophan ([11C]5-HTP) could
be used for functional imaging of the islets of Langerhans in the pan-
creatic graft by Positron Emission Tomography (PET).
Methods: Patients with variable pancreatic graft function (insulin inde-
pendent, partial graft function, non-functioning grafts) were examined
by 60 minutes dynamic PET/CT following intravenous administration
of [11C]5-HTP over the site of transplantation. Two of the patients were
then examined over the native pancreas. The uptake of the radio-
tracer was expressed as graft-to-blood (G/B) ratio to enable within-
and between-patient comparison.
Results: [11C]5-HTP displayed high uptake in patients with functional
pancreatic grafts (G/B55min 4.3 and 5.6). In patients with failing graft
function, the uptake of [11C]5-HTP was conversely markedly reduced
(G/B55min 1.1 and 1.3). Low or negligible uptake was seen in the native
non-functional pancreata. In this pilot group, there was a correlation
between serotonergic facilitation as measured by [11C]5-HTP-PET
and graft function.
Discussion: Serotonergic facilitation as measured by [11C]5-HTP-PET
seems to correlate well with the functional status of the transplanted pan-
creas. In fact, the functional grafts had a dynamic uptake similar to that of
native, healthy pancreas in non-diabetic subjects while the non-functional
grafts had a dynamic uptake similar to that in pancreas in T1D subjects,
indicating a correlation between transplanted beta cell function/mass
and serotonergic facilitation.
Conclusion: [11C]5-HTP-PET is a promising non-invasive technique for
assessment of the endocrine function of the transplanted pancreas.
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Allogeneic islet transplantation reduces glycemic variability and severe
hypoglycemia in non-uremic type-1 diabetic patients maintained on im-
mune suppression. We now report the impact of ATG-induction followed
by tacrolimus and mycophenolate mofetil (MMF) on acute and chronic
diabetic complications and its associated side-effects.
Data were collected during one (n=55) to five year (n=22) post-
transplantation (PT). ATG dose ranged from 12.6 to 29.4 mg/kg
(median 21.4), MMF was given at 1.5 gram/day (IQR 1.2 to 1.7)
and tacrolimus trough levels were 9.4 ng/dl (IQR 8.8 to 10.0) during
the first year and 7.2 ng/dl (IQR 6.2 to 8.2) until year 5 PT. The per-
centage of fasting glycemia >300 and <50 mg/dl decreased from
10 and 5% pre-transplantation respectively, to 2 (p=0.004) and
1% (p<0.001) post-transplantation. Several patients suffered from
at least one hyperglycemic ketoacidosis (n=6) or hypoglycemic
coma (n=25) in the year before transplantation but not in the 5 years
thereafter (n=0, p=0.02 and n=1, p<0.001 resp.). No progression
of micro- and macro-vascular complications was seen. Lipid profiles
and blood pressure remained unchanged.
Fifty-six serious adverse events (SAEs) were reported. One patient died
from cerebral hemorrhage at PT month 4 and one from liver metasta-
sized gastric adenocarcinoma, diagnosed at PTmonth 27. Five patients
developed CMV infections, successfully treated with intravenous (IV)
ganciclovir. Most frequent SAE were gastro-intestinal infections (18/56),
resolving with antibiotics and IV hydration.
Less severe adverse events were pyrosis (n=12), insomnia (n=12) and
headache (n=10), occurring mainly during the first year, respiratory
infections (n=23) andmusculoskeletal pain (n=18) withmore stable pre-
sentation. Memory impairment was seen in 6 patients, mostly with later
onset. Anemia, leucopenia, neutropenia were observed in >50% of
patients during the first 6 months PT, but decreased with time.
Our observations indicate that ATG-MMF–Tacrolimus regimen is safe,
but is associated with expected side effects, requiring close monitoring
for the occasional SAEs. The list of side effects should help select im-
mune therapy protocols for further trials of islet transplantation.
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